| Research and development spending to bring a single cancer drug to market and revenues after approval V Prasad, S Mailankody JAMA internal medicine 177 (11), 1569-1575, 2017 | 491 | 2017 |
| The high price of anticancer drugs: origins, implications, barriers, solutions V Prasad, K De Jesús, S Mailankody Nature reviews Clinical oncology 14 (6), 381-390, 2017 | 389 | 2017 |
| Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture T Fojo, S Mailankody, A Lo JAMA Otolaryngology–Head & Neck Surgery 140 (12), 1225-1236, 2014 | 372 | 2014 |
| Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma N Korde, M Roschewski, A Zingone, M Kwok, EE Manasanch, M Bhutani, ... JAMA oncology 1 (6), 746-754, 2015 | 329 | 2015 |
| Five years of cancer drug approvals: innovation, efficacy, and costs S Mailankody, V Prasad JAMA oncology 1 (4), 539-540, 2015 | 329 | 2015 |
| Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS) S Mailankody, RM Pfeiffer, SY Kristinsson, N Korde, M Bjorkholm, ... Blood, The Journal of the American Society of Hematology 118 (15), 4086-4092, 2011 | 234 | 2011 |
| Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis O Landgren, S Devlin, M Boulad, S Mailankody Bone marrow transplantation 51 (12), 1565-1568, 2016 | 199 | 2016 |
| Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies T Jain, A Knezevic, M Pennisi, Y Chen, JD Ruiz, TJ Purdon, SM Devlin, ... Blood advances 4 (15), 3776-3787, 2020 | 189 | 2020 |
| GPRC5D-targeted CAR T cells for myeloma S Mailankody, SM Devlin, J Landa, K Nath, C Diamonte, EJ Carstens, ... New England journal of medicine 387 (13), 1196-1206, 2022 | 158 | 2022 |
| Second malignancies after multiple myeloma: from 1960s to 2010s A Thomas, S Mailankody, N Korde, SY Kristinsson, I Turesson, ... Blood, The Journal of the American Society of Hematology 119 (12), 2731-2737, 2012 | 157 | 2012 |
| Minimal residual disease in multiple myeloma: bringing the bench to the bedside S Mailankody, N Korde, AM Lesokhin, N Lendvai, H Hassoun, ... Nature reviews Clinical oncology 12 (5), 286-295, 2015 | 151 | 2015 |
| The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma EE Sigurdardottir, I Turesson, SH Lund, EK Lindqvist, S Mailankody, ... JAMA oncology 1 (2), 168-174, 2015 | 136 | 2015 |
| Cancer drugs approved based on biomarkers and not tumor type—FDA approval of pembrolizumab for mismatch repair-deficient solid cancers V Prasad, V Kaestner, S Mailankody JAMA oncology 4 (2), 157-158, 2018 | 135 | 2018 |
| JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE) S Mailankody, M Htut, KP Lee, W Bensinger, T Devries, J Piasecki, ... Blood 132, 957, 2018 | 118 | 2018 |
| Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update … S Mailankody, AJ Jakubowiak, M Htut, LJ Costa, K Lee, S Ganguly, ... Journal of Clinical Oncology 38 (15_suppl), 8504-8504, 2020 | 117 | 2020 |
| Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health … O Landgren, BI Graubard, S Kumar, RA Kyle, JA Katzmann, K Murata, ... Blood cancer journal 7 (10), e618-e618, 2017 | 105 | 2017 |
| Emerging immunotherapies in multiple myeloma UA Shah, S Mailankody Bmj 370, 2020 | 100 | 2020 |
| Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed/refractory multiple myeloma: final results of a phase I … S Mailankody, A Ghosh, M Staehr, TJ Purdon, M Roshal, E Halton, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 87 | 2018 |
| Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results S Mailankody, JV Matous, S Chhabra, M Liedtke, S Sidana, OO Oluwole, ... Nature medicine 29 (2), 422-429, 2023 | 86 | 2023 |
| Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies R Stuver, GL Shah, NS Korde, LE Roeker, AR Mato, CL Batlevi, DJ Chung, ... Cancer Cell 40 (6), 590-591, 2022 | 82 | 2022 |
Vinay Prasad, MD MPHProfessor, University of California San FranciscoVerified email at ucsf.edu
